首页> 外文期刊>Journal of human nutrition and dietetics >Parenteral nutrition for patients with advanced ovarian malignancy
【24h】

Parenteral nutrition for patients with advanced ovarian malignancy

机译:肠外营养治疗晚期卵巢恶性肿瘤

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Parenteral nutrition (PN) in patients with disseminated ovarian cancer remains controversial. The role of PN in providing nutrition and improving quality of life is unclear. The present study aimed to determine the pattern of prescribing in a large teaching hospital, and to identify subgroups where the use of PN was justified. Methods: Sixty-five patients with advanced ovarian carcinoma received PN between January 2002 and May 2008. A retrospective case note review was undertaken to retrieve data on PN prescribing and outcomes in terms of duration of PN provision, complications, and survival. Results: Three subgroups were identified. Group I consisted of 18 (28%) patients who received PN for a median [interquartile range (IQR)] of 5 (2-11) days. The majority of these 18 patients (n = 13, 72%) had disease-related terminal bowel obstruction. Out of 18 of these patients, 17 (95%) had poor performance status. The median (IQR) survival was 12 (6-28) days. Group II consisted of 40 (61%) patients who were re-established on enteral nutrition. The median (IQR) duration of PN administration was 10 (6-17) days. The most common indication of PN was protracted ileus (n = 25, 63%). Out of 40 of these patients, 35 (88%) patients had good performance status. The median (IQR) survival was 264 (96-564) days. The third group of patients required home PN (n - 7, 11%). Four (58%) patients had short bowel syndrome and three (42%) had terminal intestinal obstruction. All of the patients had good performance status. The median (IQR) duration of PN administration and survival was 241 (90-305) days. Conclusions: Administration of PN appears to be justified in those patients with a good performance status (i.e. patients capable of self-care), which constituted three-quarters of this cohort. In the remaining patients with poor performance status, and particularly those with terminal intestinal obstruction, PN administration was difficult to justify. PN should not be denied based...
机译:背景:弥漫性卵巢癌患者的肠胃外营养(PN)仍存在争议。 PN在提供营养和改善生活质量方面的作用尚不清楚。本研究旨在确定大型教学医院的处方模式,并确定使用PN是合理的亚组。方法:2002年1月至2008年5月间,有65例晚期卵巢癌患者接受了PN。回顾性病例记录回顾了关于PN处方和结局的数据,包括PN的持续时间,并发症和生存率。结果:确定了三个亚组。第一组由18位(28%)的患者接受PN,中位[四分位间距(IQR)]为5(2-11)天。这18例患者中的大多数(n = 13,72%)患有与疾病相关的末期肠梗阻。在这些患者中的18名中,有17名(95%)的表现状态较差。中位(IQR)生存期为12(6-28)天。第二组由40位(61%)的患者通过肠内营养重建。 PN管理的中位数(IQR)持续时间为10(6-17)天。 PN的最常见指征是延长的肠梗阻(n = 25,63%)。在这些患者中的40名中,有35名(88%)的患者表现良好。中位(IQR)存活时间为264(96-564)天。第三组患者需要家庭PN(n-7、11%)。四名(58%)患有短肠综合征,三名(42%)患有终末肠梗阻。所有患者均表现良好。 PN管理和生存的中位(IQR)持续时间为241(90-305)天。结论:对于表现良好的患者(即能够自我护理的患者),PN的使用似乎是合理的,这些患者占这一队列的四分之三。在其余表现状态较差的患者中,尤其是那些终末肠梗阻的患者,PN给药很难证明其合理性。 PN不应基于...而被拒绝...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号